| Literature DB >> 30105918 |
M Junaid Dar1, Fakhar Ud Din1, Gul Majid Khan1.
Abstract
Topical drug delivery against cutaneous leishmaniasis (CL) signifies an effective alternate for improving the availability and reducing the toxicity associated with the parenteral administration of conventional sodium stibogluconate (SSG) injection. The basic aim of the study was to develop nano-deformable liposomes (NDLs) for the dermal delivery of SSG against CL. NDLs were formulated by a modified thin film hydration method and optimized via Box-Behnken statistical design. The physicochemical properties of SSG-NDLs were established in terms of vesicle size (195.1 nm), polydispersity index (0.158), zeta potential (-32.8 mV), and entrapment efficiency (35.26%). Moreover, deformability index, in vitro release, and macrophage uptake studies were also accomplished. SSG-NDLs were entrapped within Carbopol gel network for the ease of skin application. The ex vivo skin permeation study revealed that SSG-NDLs gel provided 10-fold higher skin retention towards the deeper skin layers, attained without use of classical permeation enhancers. Moreover, in vivo skin irritation and histopathological studies verified safety of the topically applied formulation. Interestingly, the cytotoxic potential of SSG-NDLs (1.3 mg/ml) was higher than plain SSG (1.65 mg/ml). The anti-leishmanial activity on intramacrophage amastigote model of Leishmania tropica showed that IC50 value of the SSG-NDLs was ∼ fourfold lower than the plain drug solution with marked increase in the selectivity index. The in vivo results displayed higher anti-leishmanial activity by efficiently healing lesion and successfully reducing parasite burden. Concisely, the outcomes indicated that the targeted delivery of SSG could be accomplished by using topically applied NDLs for the effective treatment of CL.Entities:
Keywords: Cutaneous leishmaniasis; macrophage uptake; nano-deformable liposomes; sodium stibogluconate; transfersomes
Mesh:
Substances:
Year: 2018 PMID: 30105918 PMCID: PMC6095017 DOI: 10.1080/10717544.2018.1494222
Source DB: PubMed Journal: Drug Deliv ISSN: 1071-7544 Impact factor: 6.419
Composition, entrapment efficiency, and vesicle size of SSG-NDLs.
| Run | Independent variables | Dependent variables | |||
|---|---|---|---|---|---|
| F1 | 50 | 300 | 5 | 100 ± 5.23 | 2.7 ± 0.71 |
| F2 | 50 | 200 | 10 | 89.63 ± 6.12 | 4.3 ± 1.92 |
| F3 | 75 | 300 | 10 | 137.5 ± 3.8 | 17.23 ± 4.83 |
| F4 | 50 | 400 | 10 | 157.7 ± 7.36 | 13.9 ± 5.36 |
| F5 | 75 | 400 | 15 | 231.8 ± 9.72 | 20.3 ± 3.95 |
| F6 | 50 | 300 | 15 | 69.13 ± 4.53 | 9.18 ± 5.63 |
| F7 | 100 | 400 | 10 | 195.1 ± 3.67 | 35.26 ± 6.28 |
| F8 | 75 | 400 | 5 | 213.1 ± 8.41 | 24.8 ± 4.19 |
| F9 | 75 | 300 | 10 | 153.7 ± 3.84 | 21.6 ± 7.47 |
| F10 | 75 | 200 | 15 | 35.37 ± 2.73 | 4.5 ± 2.91 |
| F11 | 75 | 200 | 5 | 187.9 ± 6.18 | 18.2 ± 5.69 |
| F12 | 100 | 300 | 5 | 114.4 ± 4.36 | 28.3 ± 7.36 |
| F13 | 100 | 200 | 10 | 92.38 ± 5.52 | 19.4 ± 3.94 |
| F14 | 75 | 300 | 10 | 170.1 ± 7.29 | 14.5 ± 5.89 |
| F15 | 100 | 300 | 15 | 58.7 ± 3.81 | 25.7 ± 6.77 |
X1: SSG concentration; X2: amount of phospholipid; X3: percentage of edge activator; Y1: vesicle size; Y2: entrapment efficiency.
Figure 1.(a) In vitro drug release study in PBS (pH 7.4) and sodium acetate (pH 5.5) buffers. (b) Ex vivo permeation study in PBS of pH 7.4. (c) Histopathological study of the skin patch treated with plain SSG, showing gaps and slight distorted skin layers. (d) Comparison of SSG percentage permeated and SSG retention in the stratum corneum and epidermis/dermis layers of the skin treated with plain SSG, SSG-NDLs, and SSG-NDLs gel.
Figure 2.(a) Images observed under normal light microscope (A and B) and corresponding fluorescent microscope (C and D) of normal (A and C) skin and FITC/SSG-NDLs treated (B and D) skin sections after 24 h topical application. (b) FTIR spectra and DSC thermogram of untreated and SSG-NDLs gel treated epidermis. (c) Hematoxylin and eosin stained cross sectional images of different skin sections of (i) blank group, (ii) formalin (0.8%), and (iii) SSG-NDLs gel groups.
Storage stability of dialyzed and un-dialyzed SSG-NDLs and SSG-NDLs gel for 60 days.
| Day | Size (nm) | PDI | Zeta potential (mV) | Entrapment efficiency (%) | Precipitation | Phase separation | Un-dialyzed vesicles | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Size (nm) | PDI | Zeta potential (mV) | |||||||||||||
| 4 °C | 25 °C | 4 °C | 25 °C | 4 °C | 25 °C | 4 °C | 25 °C | 4 °C | 25 °C | 4 °C | 25 °C | 25 °C | 25 °C | 25 °C | |
| 0 | 195.1 ± 3.67 | 195.1 ± 3.67 | 0.158 ± 0.0145 | 0.158 ± 0.0145 | −32.8 ± 0.88 | −32.8 ± 0.88 | 35.26 ± 1.8 | 35.26 ± 1.8 | No | No | No | No | 187.9 ± 3.5 | 0.143 ± 0.0422 | −7.66 ± 0.6 |
| 10 | 195.5 ± 3.19 | 198.4 ± 4.13 | 0.154 ± 0.0176 | 0.159 ± 0.0954 | −32.3 ± 0.70 | −31.8 ± 0.41 | 34.92 ± 1.4 | 34.68 ± 1.9 | No | No | No | No | 203.7 ± 1.6 | 0.161 ± 0.0648 | −6.29 ± 0.5 |
| 15 | 197.4 ± 2.74 | 205 ± 3.27 | 0.164 ± 0.0096 | 0.166 ± 0.0415 | −31.9 ± 0.82 | −29.3 ± 1.04 | 34.16 ± 1.9 | 32.34 ± 1.1 | No | No | No | No | 212.2 ± 2.9 | 0.173 ± 0.0781 | −4.91 ± 0.7 |
| 30 | 199.1 ± 1.52 | 213.2 ± 3.77 | 0.167 ± 0.0133 | 0.17 ± 0.0275 | −31.0 ± 0.91 | −29.0 ± 0.52 | 33.71 ± 0.9 | 31.22 ± 2.3 | No | No | No | No | 223.5 ± 1.1 | 0.211 ± 0.01628 | −4.53 ± 0.4 |
| 45 | 201.7 ± 3.58 | 217.9 ± 2.81 | 0.173 ± 0.0232 | 0.193 ± 0.0153 | −30.6 ± 0.50 | −27.6 ± 0.79 | 31.28 ± 1.7 | 29.77 ± 1.5 | No | No | No | No | 237.5 ± 2.5 | 0.252 ± 0.0373 | −3.27 ± 0.7 |
| 60 | 205.3 ± 2.82 | 223.5 ± 3.55 | 0.181 ± 0.0147 | 0.211 ± 0.0913 | −29.9 ± 0.65 | −26.7 ± 0.31 | 31.05 ± 2.1 | 28.93 ± 1.3 | No | No | No | No | 247 ± 3.8 | 0.276 ± 0.0843 | −2.83 ± 0.6 |
Figure 3.(a) Cytotoxicity potential of SSG solution and SSG-NDLs on the mice peritoneal macrophages. (b) Uptake of FITC/SSG-NDLs in mice peritoneal macrophages after 30 min incubation. (c) Inhibitory effect of different concentrations of SSG solution and SSG-NDLs on amastigote growth. (d) In vivo BALB/c infection model of cutaneous leishmaniasis.